Shares of Tower Semiconductor (TSEM) hit a new 52-week high Tuesday, surpassing their previous high of $16.79 set on March 2, 2015. The stock has gotten as high as $18.20 intraday. That’s a 141% rise, or $10.64 per share from the 52-week low of $7.56 set on May 8, 2014.
In the last 52 weeks shares have printed a one-year return of about 124% and year-to-date return of around 33%. Approximately 1.2 million TSEM shares have already changed hands, compared to the stock’s average daily volume of 1.3 million shares.
Tower Semiconductors is trading up more than 5 percent in Tuesday’s trading session.
Shares of Sirius XM Holdings (SIRI) hit a new 52-week high today, printing the tape intraday at $4.02. That’s a 34% rise, or $1.04 per share from the 52-week low of $2.98 set on April 28, 2014.
The stock closed at $3.96 at the end of Monday’s trading session, printing a solid one-year return of about 11.60% and year-to-date return of around 14%. Sirius is trading at a high volume Tuesday with more than 26 million shares already changing hands. The average volume of shares traded over the last three months is 33 million.
Springleaf Holdings, LLC (LEAF) shares reached a new 52-week high of $52.48 Tuesday, after the company announced that it had reached a deal to acquire OneMain Financial Holdings from Citigroup (C) for $4.25 billion in cash.
The stock surpassed its previous high of $39.86 set on December 2, 2014. That’s an almost 32% rise, or $12.62 per share from the 52-week low of $20.54 set on April 16, 2014.
Springleaf Holdings shares are currently priced at 9.61x this year’s forecasted earnings compared to the industry’s 15.93x earnings multiple. Ticker has a PEG and forward P/E ratio of 1.22 and 20.63, respectively. Price/sales for the same period is 2.53 while EPS is $5.06.
In the past 52 weeks, shares of Evansville, Indiana-based company have traded between a low of $20.54 and a high of $52.48 and are now up nearly 29% at $49. Shares are up 73% year-over-year and 34.15% year-to-date.
TRACON Pharmaceuticals, Inc. (TCON) shares touched a new high of $20.94 after the company reported positive Phase 1b results for TRC105 in combination with Inlyta.
TRACON Pharmaceuticals, Inc., currently valued at $235.49 million, has a median Wall Street price target of $20.00 with a high target of $26.00. Approximately 260K shares have already changed hands, compared to the stock’s average daily volume of 187.67K.
TCON currently prints a year-to-date return of around 122%, compared with an 12.99% gain in the S&P 500.